Rock Creek Pharmaceuticals Inc is a United States-based pharmaceutical development company. The Company is focused on the discovery, development and commercialization of therapies for chronic inflammatory disease and neurologic disorders. Its activities are focused on its lead compound, anatabine citrate (anatabine). Anatabine is a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics. The Company focuses on dermatological skin diseases, such as psoriasis, eczema and rare or orphan skin disorders, using its formulations of anatabine.

Employees

Sector

Pharmaceuticals

More about the company

08/12/20	Rock Creek Pharmaceuticals, Inc. Went Out of Business	CI
06/02/20	Bankruptcy Judge Changed for Rock Creek Pharmaceuticals, Inc.	CI

Market Cap	153K 132K 124K 113K 212K 14.48M 213K 1.47M 569K 7.43M 576K 563K 23.94M	P/E 2014	-0.87x	P/E 2015	-1.04x
Enterprise Value	20.01M 17.22M 16.2M 14.8M 27.68M 1.89B 27.76M 191M 74.29M 969M 75.14M 73.5M 3.12B	EV / Sales 2014	-	EV / Sales 2015	-
Free-Float	100%	Yield 2014 *	-	Yield 2015	-

08/12/20	Rock Creek Pharmaceuticals, Inc. Went Out of Business	CI
06/02/20	Bankruptcy Judge Changed for Rock Creek Pharmaceuticals, Inc.	CI
21/12/18	Motion for Asset Sale Filed by Rock Creek Pharmaceuticals, Inc.	CI
11/01/18	Motion for Asset Sale Approved for Rock Creek Pharmaceuticals, Inc.	CI
27/09/16	Rock Creek Pharmaceuticals, Inc. Filed for Bankruptcy	CI
30/08/16	Rock Creek Pharmaceuticals, Inc. Receives Event of Default Redemption Notice from Hudson Bay Master Fund Ltd. and from Tenor Capital Management on Behalf of Alto Opportunity Master Fund	CI
11/08/16	Rock Creek Pharmaceuticals, Inc. Announces Earnings Results for the Second Quarter Ended June 30, 2016	CI
09/07/16	Rock Creek Pharmaceuticals, Inc. Announces Board Changes	CI
08/06/16	Rock Creek Pharmaceuticals, Inc. Reports Earnings results for the First Quarter Ended March 31, 2016	CI
30/03/16	Rock Creek Pharmaceuticals, Inc. announced that it has received $0.5 million in funding.	CI
23/03/16	Rock Creek Pharmaceuticals, Inc. Announces Earnings Results for the Year Ended December 31, 2015	CI
22/03/16	Rock Creek Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
19/11/15	Rock Creek Pharmaceuticals, Inc. Appoints Robert Scannell as Director	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-0.88%	-2.15%	+54.71%	+106.31%	1,024B
JOHNSON & JOHNSON	-1.15%	+2.68%	+53.97%	+71.50%	663B
ABBVIE INC.	-1.44%	+0.38%	+20.40%	+73.05%	453B
ROCHE HOLDING AG	+0.14%	-0.47%	+29.49%	+38.56%	352B
NOVARTIS AG	-1.33%	+4.72%	+24.69%	+45.55%	304B
ASTRAZENECA PLC	-1.15%	+0.30%	-1.49%	+12.31%	252B
AMGEN INC.	-1.55%	+1.11%	+56.10%	+70.32%	236B
NOVO NORDISK A/S	-0.88%	+1.15%	-17.09%	-54.39%	206B
GILEAD SCIENCES, INC.	-0.15%	+3.65%	+33.90%	+96.99%	187B
Average	-0.99%	+1.09%	+28.30%	+51.13%	408.71B
Weighted average by Cap.	-1.10%	+0.55%	+36.62%	+66.22%

	2014	2015
Net sales	-	-
Net income	-38.52M -33.14M -31.18M -28.49M -53.29M -3.64B -53.43M -368M -143M -1.87B -145M -141M -6.01B	-6.84M -5.89M -5.54M -5.06M -9.47M -646M -9.5M -65.49M -25.41M -332M -25.7M -25.14M -1.07B
Net Debt	-45K -38.72K -36.43K -33.28K -62.26K -4.25M -62.43K -431K -167K -2.18M -169K -165K -7.02M	19.86M 17.09M 16.08M 14.69M 27.47M 1.87B 27.55M 190M 73.72M 962M 74.57M 72.94M 3.1B

Star Scientific, Inc. Stock Nasdaq

Stocks

US85517P1012

Pharmaceuticals

Valuation : Star Scientific, Inc.

Latest news : Star Scientific, Inc.

Analysts' recommendations : Star Scientific, Inc.

Other Pharmaceuticals

Financials

Company Profile

End-of-day quote Nasdaq
- ^USD	-